Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.
Synairgen engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease and severe viral infections, as well as COVID-19. The company was founded by Donna E. Davies, Ratko Djukanovic, and Stephen T. Holgate in June 2003 and is headquartered in Southampton.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as advisor to Synairgen plc in this transaction.
CEO, Synairgen plc
Sprechen Sie mit dem Deal Team
Laptaria cu Caimac has completed an IPO
Laptaria cu Caimac has raised US$5 million through a private placement of shares on the ATS Market of BSE. The funds will be used for the development of the factory, namely, the construction of a bottle and jar washing station, utility systems and packaging storage.Mehr erfahren
Nutricare has raised 3.1 million via an entitlement offer
Nutricare Pty Ltd has raised funds to support its growth strategy.Mehr erfahren
Alexandria Pankkiiriliike Oyj has raised US$9.7m in the course of its IPO on NASDAQ First North Finland
Alexandria Pankkiiriliike Oyj (Alexandria) has raised US$9.7 million in the course of its IPO.Mehr erfahren